CXCL8 and neoplasm: Average endpoint tumor weights demonstrated significant reduction following enzalutamide/anti-VEGF (P = 0.0144; or enzalutamide/anti-VEGF/IL8 (P = 0.0009) compared with vehicle (Fig. 3G).